Betta Pharmaceuticals Hits Day Low of CNY 47.57 Amid Price Pressure

Betta Pharmaceuticals Co., Ltd. experienced a notable decline in its stock performance on June 2, 2026, with a loss of 5.64%. The stock reached an intraday low of CNY 47.57, reflecting ongoing challenges in the market. Over the past year, Betta Pharmaceuticals has generated a return of -15.17%, significantly underperforming the China Shanghai Composite, which has seen a gain of 21.74% during the same period. In terms of financial metrics, the company has reported a modest annual growth rate in net sales of 12.42% over the last five years, while operating profit has increased at a rate of 5.21%. The return on equity stands at 6.74%, indicating a relatively low profitability level compared to its valuation, which is reflected in a price-to-book ratio of 3.12. Additionally, the stock offers a dividend yield of 0.39%, which may appeal to some investors despite the overall negative performance. Betta Pharmaceuticals' market capitalization is approximately CNY 20,911 million, categorizing it as a large-cap company within the pharmaceuticals and biotechnology industry.